{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:34:32Z","timestamp":1788957272180,"version":"build-2803163510"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Type 2 diabetes mellitus (T2DM) severely increases the probability of developing coronary artery disease (CAD), and diabetic patients with CAD should be considered at very high cardiovascular risk. The complexity of this clinical scenario makes very hard the appropriateness of the pharmacological treatment in the real world. To investigate the implementation of guideline recommendations for the treatment of patients affected by CAD with or without T2DM, a retrospective observational study was carried out between 2018 and 2020, by using the computerized clinical medical record of 10 general practitioners (GPs) including 13,206 subjects. A total of 926 patients (7.0%) were affected by CAD and 393 (42.4%) of them were also diabetic. LDLc, SBP, DBP, and FPG were recorded in 77.4%, 65.4%, 66.5%, and 82.6% of patients, respectively. Comorbidities (median; IQR = 8; 6\u201310 vs. 5; 3\u20137: <jats:italic>p<\/jats:italic> &amp;lt; 0.001) were significantly high in diabetic patients. Specialist counselling has been observed in 59.9% of diabetic and 57% of non-diabetic patients (<jats:italic>p<\/jats:italic> = 0.400). Antithrombotic drugs, statins, \u03b2-blockers, or RAASs were prescribed in 67.2%, 59.6%, and 75.9% of patients, respectively. Overall, 462 (49.9%) patients used the treatment suggested by guidelines. Dyslipidemia, hypertension, atherosclerosis, and specialist counselling were predictors of suggested drugs use both in diabetic and non-diabetic patients. Diabetes was not an independent factor related to the likelihood to be properly treated, according to the guidelines. Glucose lowering drugs were prescribed in 69.5% of diabetic patients, but only 39 (14.3%) were treated with the proper GLP-1 or SGLT2-i, whereas 45 patients (16.5%) received the improper sulphonylureas. Our results showed that a \u201cnon-ideal\u201d therapeutic approach was adopted in patients affected by diabetes and CAD. ADA and ESC guidelines recommend the use of at least one hypoglycemic agent belonging to the GLP-1 or SGLT2-i class in diabetic patients with high\/very high cardiovascular risk, regardless of the glycemic target (HbA1c &amp;lt;7%). However, only a few diabetic patients on hypoglycemic therapy were appropriately treated. These data suggest that a closer collaboration between the GPs, clinical pharmacologist, and specialists is needed in the real world scenario of the general practice in order to effectively improve adherence to guidelines and overall management of global cardiovascular risk in diabetic patients.<\/jats:p>","DOI":"10.3389\/fphar.2022.858385","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:41:15Z","timestamp":1648514475000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacological Treatment of Diabetic and Non-Diabetic Patients With Coronary Artery Disease in the Real World of General Practice"],"prefix":"10.3389","volume":"13","author":[{"given":"Michelangelo","family":"Rottura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Molonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico Antonio","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Scoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Irrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egidio","family":"Imbalzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Altavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Squadrito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Squadrito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Arcoraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrneph.2015.37","article-title":"The Genetics of Diabetic Complications","volume":"11","author":"Ahlqvist","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2174\/187152509789541909","article-title":"Polydeoxyribonucleotide (PDRN): A Safe Approach to Induce Therapeutic Angiogenesis in Peripheral Artery Occlusive Disease and in Diabetic Foot Ulcers","volume":"7","author":"Altavilla","year":"2009","journal-title":"Cardiovasc. Hematological Agents Med. Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.3390\/jcm9051346","article-title":"Chronic Kidney Disease Management in General Practice: A Focus on Inappropriate Drugs Prescriptions","volume":"9","author":"Barbieri","year":"2020","journal-title":"J. Clin. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart Disease and Stroke Statistics\u20142017 Update: A Report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases Developed in Collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1097\/01.hjh.0000173526.65555.55","article-title":"The Use of a Telematic Connection for the Follow-Up of Hypertensive Patients Improves the Cardiovascular Prognosis","volume":"23","author":"De Luca","year":"2005","journal-title":"J. Hypertens."},{"key":"B7","doi-asserted-by":"publisher","first-page":"101337","DOI":"10.1016\/j.molmet.2021.101337","article-title":"Sodium-Glucose Co-Transporter2 Expression and Inflammatory Activity in Diabetic Atherosclerotic Plaques: Effects of Sodium-Glucose Co-Transporter2 Inhibitor Treatment","volume":"54","author":"D\u2019Onofrio","year":"2021","journal-title":"Mol. Metab."},{"key":"B8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrcardio.2010.162","article-title":"Cardiovascular Drug Therapy in the Elderly: Benefits and Challenges","volume":"8","author":"Fleg","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4i","DOI":"10.1016\/j.amjcard.2007.03.002","article-title":"Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial","volume":"99","author":"Goff","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"107609","DOI":"10.1016\/j.jdiacomp.2020.107609","article-title":"Coronary Artery Calcification, Carotid Intima-media Thickness and Cardiac Dysfunction in Young Adults with Type 2 Diabetes Mellitus","volume":"34","author":"Joseph","year":"2020","journal-title":"J. Diabetes its Complications"},{"key":"B11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1076-7460.2002.00995.x","article-title":"Coronary Heart Disease Risk Factors in the Elderly","volume":"11","author":"Kannel","year":"2002","journal-title":"Am. J. Geriatr. Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00592-021-01705-x","article-title":"Evidence for Human Diabetic Cardiomyopathy","volume":"58","author":"Marfella","year":"2021","journal-title":"Acta Diabetol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e13737","DOI":"10.1111\/eci.13737","article-title":"Coronary Microvascular Disease: The \u201cMeeting Point\u201d of Cardiology, Rheumatology and Endocrinology","author":"Markousis\u2010Mavrogenis","year":"2022","journal-title":"Eur. J. Clin. Invest."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.3390\/ijms22083850","article-title":"Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches","volume":"22","author":"Medina-Leyte","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40256-014-0094-z","article-title":"Role of Vascular Inflammation in Coronary Artery Disease: Potential of Anti-Inflammatory Drugs in the Prevention of Atherothrombosis: Inflammation and Anti-Inflammatory Drugs in Coronary Artery Disease","volume":"15","author":"Moreira","year":"2015","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1097\/01.hjh.0000334072.97080.33","article-title":"Blood Pressure Control, Risk Factors and Cardiovascular Prognosis in Patients with Diabetes: 30 Years of Progress","volume":"26","author":"Mourad","year":"2008","journal-title":"J. Hypertens."},{"key":"B18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2165\/00129784-200505060-00005","article-title":"Beyond Low-Density Lipoprotein: Addressing the Atherogenic Lipid Triad in Type 2 Diabetes Mellitus and the Metabolic Syndrome","volume":"5","author":"Nesto","year":"2005","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes","volume":"41","author":"Neumann","year":"2020","journal-title":"Eur. Heart J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.2337\/dci21-0042","article-title":"Impact of Admission Hyperglycemia on Heart Failure Events and Mortality in Patients with Takotsubo Syndrome at Long-Term Follow-Up: Data from HIGH-GLUCOTAKO Investigators","volume":"44","author":"Paolisso","year":"2021","journal-title":"Diabetes Care"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1524-4733.2006.00139.x","article-title":"A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases","volume":"10","author":"Peterson","year":"2007","journal-title":"Value in Health"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/j.amjcard.2011.01.052","article-title":"Adherence to Statins, Subsequent Healthcare Costs, and Cardiovascular Hospitalizations","volume":"107","author":"Pittman","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.jacc.2015.07.018","article-title":"Long-Term Use of Cardiovascular Drugs","volume":"66","author":"Rossello","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"749686","DOI":"10.3389\/fcvm.2021.749686","article-title":"Management of High Cardiovascular Risk in Diabetic Patients: Focus on Low Density Lipoprotein Cholesterol and Appropriate Drug Use in General Practice","volume":"8","author":"Rottura","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"108086","DOI":"10.1016\/j.diabres.2020.108086","article-title":"Mortality Attributable to Diabetes in 20\u201379 Years Old Adults, 2019 Estimates: Results from the International Diabetes Federation Diabetes Atlas, 9th Edition","volume":"162","author":"Saeedi","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B26","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s13643-021-01841-z","article-title":"Prognostic Models of Diabetic Microvascular Complications: a Systematic Review and Meta-Analysis","volume":"10","author":"Saputro","year":"2021","journal-title":"Syst. Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.2174\/1381612826666200213123029","article-title":"Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets","volume":"26","author":"Sardu","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"B28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12933-018-0778-9","article-title":"Cardiac Resynchronization Therapy with a Defibrillator (CRTd) in Failing Heart Patients with Type 2 Diabetes Mellitus and Treated by Glucagon-like Peptide 1 Receptor Agonists (GLP-1 RA) Therapy vs. Conventional Hypoglycemic Drugs: Arrhythmic burden, Hospitalizations for Heart Failure, and CRTd Responders Rate","volume":"17","author":"Sardu","year":"2018","journal-title":"Cardiovasc. Diabetology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 Diabetes and Incidence of Cardiovascular Diseases: A Cohort Study in 1\u00b79 Million People","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e18145","DOI":"10.7759\/cureus.18145","article-title":"Type 2 Diabetes and Causes of Sudden Cardiac Death: A Systematic Review","volume":"13","author":"Singh","year":"2021","journal-title":"Cureus"},{"key":"B31","doi-asserted-by":"publisher","first-page":"110320","DOI":"10.1016\/j.biopha.2020.110320","article-title":"Anti-Obesity Drug Therapy in Clinical Practice: Evidence of a Poor Prescriptive Attitude","volume":"128","author":"Squadrito","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/0895-4356(96)00025-X","article-title":"Inappropriate Use of Bivariable Analysis to Screen Risk Factors for Use in Multivariable Analysis","volume":"49","author":"Sun","year":"1996","journal-title":"J. Clin. Epidemiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/nejmoa0802987","article-title":"Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes","volume":"358","year":"2008","journal-title":"New Engl. J. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1056\/nejmoa052187","article-title":"Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes","volume":"353","year":"2005","journal-title":"New Engl. J. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes Mellitus, Fasting Blood Glucose Concentration, and Risk of Vascular Disease: A Collaborative Meta-Analysis of 102 Prospective Studies","volume":"375","year":"2010","journal-title":"The Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10654-019-00494-6","article-title":"Principles of Confounder Selection","volume":"34","author":"VanderWeele","year":"2019","journal-title":"Eur. J. Epidemiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"646233","DOI":"10.3389\/fendo.2021.646233","article-title":"Mesenchymal Stem Cell Exosomes as a New Strategy for the Treatment of Diabetes Complications","volume":"12","author":"Xiong","year":"2021","journal-title":"Front. Endocrinol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.858385\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:41:17Z","timestamp":1648514477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.858385\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":37,"alternative-id":["10.3389\/fphar.2022.858385"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.858385","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"article-number":"858385"}}